Combination therapy for relapsed CNS lymphoma
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug combination for people with central nervous system (CNS) lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help control the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of an aggressive B-cell lymphoma that has spread to the brain, spinal cord, or eyes.
- You have had at least one prior treatment for your CNS lymphoma, including high-dose methotrexate (or you were not able to receive it).
- You have measurable disease, such as a tumor seen on an MRI or lymphoma cells in your spinal fluid.
- You are generally able to care for yourself (ECOG performance status 0-3, with some exceptions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs for people with central nervous system (CNS) lymphoma that has come back or not responded to treatment, or for those who cannot take standard chemotherapy. The goal is to see if this new combination is safe and effective.
This trial tests a combination of two targeted drugs (loncastuximab tesirine and rituximab) given after focused radiation (SRS) for people with CNS lymphoma that has come back or not responded to treatment, or who cannot get standard high-dose methotrexate. The goal is to see if this approach is safe and effective.
This trial tests a new combination of three drugs (golcadomide, poseltinib, and rituximab) for people with diffuse large B-cell lymphoma that has returned or not responded to prior treatment. It may be an option if you cannot have a stem cell transplant.
This trial tests a combination of three drugs (poseltinib, rituximab, and lenalidomide) for people with primary central nervous system lymphoma that has come back or not responded to earlier treatment. The goal is to see if this new mix can help control the disease.
This trial tests a combination of radiation, immune-boosting drugs, and a targeted antibody for people newly diagnosed with primary central nervous system diffuse large B-cell lymphoma (a type of brain lymphoma). The goal is to see if this approach is safe and effective.
This trial tests a combination of two drugs, tafasitamab and lenalidomide, for people whose central nervous system lymphoma has come back. The goal is to see if this treatment can help shrink the cancer or slow its growth.
Hear when a new Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.